# Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer

> **NCT00080613** · PHASE2 · WITHDRAWN · sponsor: **Robert H. Lurie Cancer Center**

## Conditions studied

- Stage II Breast Cancer
- Stage IIIA Breast Cancer
- Stage IIIB Breast Cancer
- Stage IIIC Breast Cancer

## Interventions

- **DRUG:** exemestane
- **PROCEDURE:** adjuvant therapy
- **PROCEDURE:** aromatase inhibition
- **PROCEDURE:** conventional surgery
- **PROCEDURE:** endocrine therapy
- **PROCEDURE:** hormone therapy
- **PROCEDURE:** neoadjuvant therapy
- **PROCEDURE:** surgery

## Key facts

- **NCT ID:** NCT00080613
- **Lead sponsor:** Robert H. Lurie Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2013-07-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00080613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00080613, "Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00080613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*